99 related articles for article (PubMed ID: 2021798)
1. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy.
Millar WT
Br J Radiol; 1991 Mar; 64(759):242-51. PubMed ID: 2021798
[TBL] [Abstract][Full Text] [Related]
2. Application of radiobiological dosimetry to radionuclide directed therapy.
Millar WT
Br J Cancer Suppl; 1990 Jul; 10():78-80. PubMed ID: 2383484
[TBL] [Abstract][Full Text] [Related]
3. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix.
Leborgne F; Fowler JF; Leborgne JH; Zubizarreta E; Chappell R
Radiat Oncol Investig; 1997; 5(6):289-99. PubMed ID: 9436246
[TBL] [Abstract][Full Text] [Related]
4. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
[TBL] [Abstract][Full Text] [Related]
5. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
6. Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model.
Dale RG
Br J Radiol; 1989 Mar; 62(735):241-4. PubMed ID: 2702381
[TBL] [Abstract][Full Text] [Related]
7. Sublethal damage repair times for a late-responding tissue relevant to brachytherapy (and external-beam radiotherapy): implications for new brachytherapy protocols.
Brenner D; Armour E; Corry P; Hall E
Int J Radiat Oncol Biol Phys; 1998 Apr; 41(1):135-8. PubMed ID: 9588928
[TBL] [Abstract][Full Text] [Related]
8. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
Wang CJ; Huang EY; Sun LM; Chen HC; Fang FM; Hsu HC; Changchien CC; Leung SW
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):179-89. PubMed ID: 15093915
[TBL] [Abstract][Full Text] [Related]
9. Compensation for changes in dose-rate in radical low-dose-rate brachytherapy: a radiobiological analysis of a randomised clinical trial.
Roberts SA; Hendry JH; Swindell R; Wilkinson JM; Hunter RD
Radiother Oncol; 2004 Jan; 70(1):63-74. PubMed ID: 15036854
[TBL] [Abstract][Full Text] [Related]
10. A generalized linear-quadratic model incorporating reciprocal time pattern of radiation damage repair.
Huang Z; Mayr NA; Lo SS; Wang JZ; Jia G; Yuh WT; Johnke R
Med Phys; 2012 Jan; 39(1):224-30. PubMed ID: 22225291
[TBL] [Abstract][Full Text] [Related]
11. The radiobiology of conventional radiotherapy and its application to radionuclide therapy.
Dale R; Carabe-Fernandez A
Cancer Biother Radiopharm; 2005 Feb; 20(1):47-51. PubMed ID: 15778580
[TBL] [Abstract][Full Text] [Related]
12. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
Armpilia CI; Dale RG; Coles IP; Jones B; Antipas V
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):378-85. PubMed ID: 12527051
[TBL] [Abstract][Full Text] [Related]
13. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?
Konijnenberg MW
Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958
[TBL] [Abstract][Full Text] [Related]
14. The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships.
Brenner DJ; Hlatky LR; Hahnfeldt PJ; Huang Y; Sachs RK
Radiat Res; 1998 Jul; 150(1):83-91. PubMed ID: 9650605
[TBL] [Abstract][Full Text] [Related]
15. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic formulation of a lineal-quadratic-linear (LQL) model: split-dose experiments and exponentially decaying sources.
Guerrero M; Carlone M
Med Phys; 2010 Aug; 37(8):4173-81. PubMed ID: 20879577
[TBL] [Abstract][Full Text] [Related]
17. Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides.
Howell RW; Goddu SM; Rao DV
J Nucl Med; 1994 Nov; 35(11):1861-9. PubMed ID: 7965170
[TBL] [Abstract][Full Text] [Related]
18. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained.
Abou-Jaoudé W; Dale R
Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877
[TBL] [Abstract][Full Text] [Related]
19. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
20. Preclinical animal research on therapy dosimetry with dual isotopes.
Konijnenberg MW; de Jong M
Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S19-27. PubMed ID: 21484379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
